These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23794313)

  • 1. Prognostic value of somatostatin receptor-2 positivitiy in gastroenteropancreatic neuroendocrine tumors in reference to known prognostic factors.
    Yenıay L; Gürcü B; Ünalp Ö; Yilmaz F; Nart D; Sözbılen M; Çoker A
    Turk J Gastroenterol; 2012; 23(6):736-40. PubMed ID: 23794313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
    Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
    BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.
    Ezziddin S; Adler L; Sabet A; Pöppel TD; Grabellus F; Yüce A; Fischer HP; Simon B; Höller T; Biersack HJ; Nagarajah J
    J Nucl Med; 2014 Aug; 55(8):1260-6. PubMed ID: 24876204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.
    Kaemmerer D; Träger T; Hoffmeister M; Sipos B; Hommann M; Sänger J; Schulz S; Lupp A
    Oncotarget; 2015 Sep; 6(29):27566-79. PubMed ID: 26259237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
    Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
    Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?
    Milione M
    Endocrine; 2018 Jan; 59(1):1-3. PubMed ID: 28417314
    [No Abstract]   [Full Text] [Related]  

  • 8. Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin.
    Mai R; Kaemmerer D; Träger T; Neubauer E; Sänger J; Baum RP; Schulz S; Lupp A
    Sci Rep; 2019 Mar; 9(1):4339. PubMed ID: 30867449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors.
    Schillaci O; Spanu A; Scopinaro F; Falchi A; Danieli R; Marongiu P; Pisu N; Madeddu G; Delle Fave G; Madeddu G
    J Nucl Med; 2003 Mar; 44(3):359-68. PubMed ID: 12621001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A.
    Roininen N; Takala S; Haapasaari KM; Jukkola-Vuorinen A; Mattson J; Heikkilä P; Karihtala P
    Oncology; 2019; 96(3):147-155. PubMed ID: 30282082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
    Lambertini C; Barzaghi-Rinaudo P; D'Amato L; Schulz S; Nuciforo P; Schmid HA
    Regul Pept; 2013 Nov; 187():35-41. PubMed ID: 24188818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.
    Pape UF; Jann H; Müller-Nordhorn J; Bockelbrink A; Berndt U; Willich SN; Koch M; Röcken C; Rindi G; Wiedenmann B
    Cancer; 2008 Jul; 113(2):256-65. PubMed ID: 18506737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.
    Ezziddin S; Logvinski T; Yong-Hing C; Ahmadzadehfar H; Fischer HP; Palmedo H; Bucerius J; Reinhardt MJ; Biersack HJ
    J Nucl Med; 2006 Feb; 47(2):223-33. PubMed ID: 16455627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues.
    Reubi JC; Laissue J; Waser B; Horisberger U; Schaer JC
    Ann N Y Acad Sci; 1994 Sep; 733():122-37. PubMed ID: 7978860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
    Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
    Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial-mesenchymal transition markers in the differential diagnosis of gastroenteropancreatic neuroendocrine tumors.
    Galván JA; Astudillo A; Vallina A; Fonseca PJ; Gómez-Izquierdo L; García-Carbonero R; González MV
    Am J Clin Pathol; 2013 Jul; 140(1):61-72. PubMed ID: 23765535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors.
    Scherübl H; Bäder M; Fett U; Hamm B; Schmidt-Gayk H; Koppenhagen K; Dop FJ; Riecken EO; Wiedenmann B
    Gastroenterology; 1993 Dec; 105(6):1705-9. PubMed ID: 7902821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
    Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H
    Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The significance of CD44 expression in gastrointestinal neuroendocrine tumors.
    Lai CH; Shan YS; Sy ED; Hsieh YH; Tsai HW; Lee JC; Lin PW
    Hepatogastroenterology; 2005; 52(64):1071-6. PubMed ID: 16001632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.